Evotec SE ADR (EVO) - Net Assets

Latest as of March 2026: $700.35 Million USD

Based on the latest financial reports, Evotec SE ADR (EVO) has net assets worth $700.35 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.64 Billion) and total liabilities ($941.17 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check EVO tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets $700.35 Million
% of Total Assets 42.66%
Annual Growth Rate 15.22%
5-Year Change -40.96%
10-Year Change 280.19%
Growth Volatility 37.58

Evotec SE ADR - Net Assets Trend (2003–2025)

This chart illustrates how Evotec SE ADR's net assets have evolved over time, based on quarterly financial data. See how many days can Evotec SE ADR fund operations to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Evotec SE ADR (2003–2025)

The table below shows the annual net assets of Evotec SE ADR from 2003 to 2025. For live valuation and market cap data, see EVO market cap overview.

Year Net Assets Change
2025-12-31 $813.36 Million -14.61%
2024-12-31 $952.52 Million -14.95%
2023-12-31 $1.12 Billion -5.67%
2022-12-31 $1.19 Billion -13.83%
2021-12-31 $1.38 Billion +55.42%
2020-12-31 $886.41 Million +65.54%
2019-12-31 $535.47 Million +26.03%
2018-12-31 $424.88 Million +28.07%
2017-12-31 $331.75 Million +55.07%
2016-12-31 $213.94 Million +14.35%
2015-12-31 $187.09 Million +18.13%
2014-12-31 $158.38 Million -0.37%
2013-12-31 $158.97 Million +4.21%
2012-12-31 $152.55 Million +3.60%
2011-12-31 $147.25 Million +11.01%
2010-12-31 $132.64 Million +18.97%
2009-12-31 $111.49 Million -25.61%
2008-12-31 $149.86 Million -12.13%
2007-12-31 $170.55 Million +24.33%
2006-12-31 $137.18 Million -7.73%
2005-12-31 $148.67 Million +140.85%
2004-12-31 $61.73 Million +71.32%
2003-12-31 $36.03 Million --

Equity Component Analysis

This analysis shows how different components contribute to Evotec SE ADR's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 77555677800.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock $177.70 Million 21.85%
Other Comprehensive Income $-45.09 Million -5.54%
Other Components $1.46 Billion 179.05%
Total Equity $813.36 Million 100.00%

Evotec SE ADR Competitors by Market Cap

The table below lists competitors of Evotec SE ADR ranked by their market capitalization.

Company Market Cap
Via Transportation, Inc.
NASDAQ:VIA
 $1.15 Billion
Reit 1
TA:RIT1
 $1.15 Billion
ABOUT YOU Holding AG
F:YOU
 $1.15 Billion
Suofeiya Home Collection Co Ltd
SHE:002572
 $1.15 Billion
Chengdu Gas Group Co Ltd
SHG:603053
 $1.15 Billion
Limin Chemical Co Ltd
SHE:002734
 $1.15 Billion
Hiecise Precision Equipment Co Ltd
SHE:300809
 $1.15 Billion
Ambea AB
ST:AMBEA
 $1.15 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Evotec SE ADR's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 952,525,000 to 813,357,682, a change of -139,167,318 (-14.6%).
  • Net loss of 99,431,462 reduced equity.
  • Share repurchases of 1,548,000 reduced equity.
  • Other comprehensive income decreased equity by 37,739,802.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $-99.43 Million -12.22%
Share Repurchases $1.55 Million -0.19%
Other Comprehensive Income $-37.74 Million -4.64%
Other Changes $-448.05K -0.06%
Total Change $- -14.61%

Book Value vs Market Value Analysis

This analysis compares Evotec SE ADR's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.41x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has increased from 0.06x to 1.41x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2001-12-31 $57.82 $3.23 x
2002-12-31 $15.64 $3.23 x
2003-12-31 $-34.72 $3.23 x
2004-12-31 $1.41 $3.23 x
2005-12-31 $2.76 $3.23 x
2006-12-31 $2.34 $3.23 x
2007-12-31 $1.19 $3.23 x
2008-12-31 $0.79 $3.23 x
2009-12-31 $0.52 $3.23 x
2010-12-31 $0.61 $3.23 x
2011-12-31 $0.63 $3.23 x
2012-12-31 $0.65 $3.23 x
2013-12-31 $0.66 $3.23 x
2014-12-31 $0.60 $3.23 x
2015-12-31 $0.67 $3.23 x
2016-12-31 $0.80 $3.23 x
2017-12-31 $1.14 $3.23 x
2018-12-31 $1.44 $3.23 x
2019-12-31 $1.79 $3.23 x
2020-12-31 $2.88 $3.23 x
2021-12-31 $4.14 $3.23 x
2022-12-31 $3.36 $3.23 x
2023-12-31 $6.33 $3.23 x
2024-12-31 $2.69 $3.23 x
2025-12-31 $2.29 $3.23 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Evotec SE ADR utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -12.22%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -13.13%
  • • Asset Turnover: 0.43x
  • • Equity Multiplier: 2.19x
  • Recent ROE (-12.22%) is above the historical average (-14.07%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2001 -35.26% 0.00% 0.00x 1.00x $-16.39 Million
2002 -127.77% 0.00% 0.00x 1.00x $-25.77 Million
2003 0.00% -930.49% 0.09x 0.00x $-27.01 Million
2004 -48.25% -1521.56% 0.03x 1.16x $-35.57 Million
2005 -22.59% -52.38% 0.34x 1.25x $-48.45 Million
2006 -23.67% -48.21% 0.33x 1.50x $-46.19 Million
2007 -6.54% -33.92% 0.16x 1.22x $-28.21 Million
2008 -52.24% -197.63% 0.22x 1.22x $-93.27 Million
2009 -41.03% -106.59% 0.29x 1.32x $-56.58 Million
2010 2.47% 5.90% 0.29x 1.45x $-9.96 Million
2011 4.58% 8.42% 0.37x 1.48x $-7.98 Million
2012 1.62% 2.84% 0.39x 1.48x $-12.78 Million
2013 -16.00% -29.59% 0.38x 1.43x $-41.33 Million
2014 -4.41% -7.80% 0.40x 1.42x $-22.82 Million
2015 8.90% 12.94% 0.44x 1.56x $-2.03 Million
2016 12.92% 16.73% 0.47x 1.65x $6.23 Million
2017 7.33% 9.42% 0.39x 2.02x $-8.82 Million
2018 19.85% 22.42% 0.49x 1.82x $41.77 Million
2019 7.13% 8.55% 0.32x 2.58x $-15.39 Million
2020 0.71% 1.25% 0.27x 2.07x $-82.36 Million
2021 15.64% 34.87% 0.28x 1.62x $77.74 Million
2022 -14.80% -23.38% 0.33x 1.90x $-294.37 Million
2023 -7.49% -10.74% 0.34x 2.05x $-195.90 Million
2024 -20.59% -24.60% 0.42x 2.01x $-291.33 Million
2025 -12.22% -13.13% 0.43x 2.19x $-180.77 Million

Industry Comparison

This section compares Evotec SE ADR's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $379,169,986
  • Average return on equity (ROE) among peers: -14.92%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Evotec SE ADR (EVO) $700.35 Million -35.26% 1.34x $1.15 Billion
Aurora Cannabis Inc (ACB) $521.74 Million -156.52% 0.78x $172.65 Million
Akanda Corp (AKAN) $-11.99 Million 0.00% 0.00x $7.56 Million
Akebia Ther (AKBA) $635.93 Million -27.03% 0.57x $273.24 Million
Alkermes Plc (ALKS) $1.21 Billion -17.23% 0.43x $7.42 Billion
Amylyx Pharmaceuticals Inc (AMLX) $433.43 Million 11.37% 0.19x $1.64 Billion
Amphastar P (AMPH) $445.52 Million 13.94% 0.51x $854.96 Million
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) $-44.54 Million 0.00% 0.00x $5.19 Billion
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) $366.97 Million 2.90% 9.74x $3.57 Billion
Anika Therapeutics Inc (ANIK) $37.89 Million 15.55% 0.65x $189.34 Million
ANI Pharmaceuticals Inc (ANIP) $197.26 Million 7.85% 1.18x $1.80 Billion

About Evotec SE ADR

NASDAQ:EVO USA Drug Manufacturers - Specialty & Generic
Market Cap
$1.15 Billion
Market Cap Rank
#8477 Global
#2391 in USA
Share Price
$3.23
Change (1 day)
-2.12%
52-Week Range
$2.31 - $4.73
All Time High
$26.53
Categories
Companies in USA Drug Manufacturers - Specialty & Generic
About

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more